1. Home
  2. ABVX vs LYTS Comparison

ABVX vs LYTS Comparison

Compare ABVX & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABVX
  • LYTS
  • Stock Information
  • Founded
  • ABVX 2013
  • LYTS 1976
  • Country
  • ABVX France
  • LYTS United States
  • Employees
  • ABVX N/A
  • LYTS N/A
  • Industry
  • ABVX
  • LYTS Building Products
  • Sector
  • ABVX
  • LYTS Consumer Discretionary
  • Exchange
  • ABVX Nasdaq
  • LYTS Nasdaq
  • Market Cap
  • ABVX 511.3M
  • LYTS 518.5M
  • IPO Year
  • ABVX N/A
  • LYTS N/A
  • Fundamental
  • Price
  • ABVX $66.49
  • LYTS $18.83
  • Analyst Decision
  • ABVX Buy
  • LYTS Strong Buy
  • Analyst Count
  • ABVX 7
  • LYTS 2
  • Target Price
  • ABVX $65.71
  • LYTS $26.00
  • AVG Volume (30 Days)
  • ABVX 2.8M
  • LYTS 97.4K
  • Earning Date
  • ABVX 08-11-2025
  • LYTS 08-14-2025
  • Dividend Yield
  • ABVX N/A
  • LYTS 1.06%
  • EPS Growth
  • ABVX N/A
  • LYTS N/A
  • EPS
  • ABVX N/A
  • LYTS 0.72
  • Revenue
  • ABVX $11,444,012.00
  • LYTS $547,316,000.00
  • Revenue This Year
  • ABVX $284.20
  • LYTS $21.02
  • Revenue Next Year
  • ABVX N/A
  • LYTS $7.32
  • P/E Ratio
  • ABVX N/A
  • LYTS $26.15
  • Revenue Growth
  • ABVX 128.98
  • LYTS 17.89
  • 52 Week Low
  • ABVX $4.77
  • LYTS $13.63
  • 52 Week High
  • ABVX $72.90
  • LYTS $25.50
  • Technical
  • Relative Strength Index (RSI)
  • ABVX 92.92
  • LYTS 72.62
  • Support Level
  • ABVX $9.96
  • LYTS $17.30
  • Resistance Level
  • ABVX $72.90
  • LYTS $18.15
  • Average True Range (ATR)
  • ABVX 1.84
  • LYTS 0.43
  • MACD
  • ABVX 6.88
  • LYTS 0.05
  • Stochastic Oscillator
  • ABVX 90.17
  • LYTS 97.02

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

About LYTS LSI Industries Inc.

LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Lighting segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays and custom display elements.

Share on Social Networks: